Average Insider

Where insiders trade, we follow

$PRME
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Allan Reine
CEO
214
Employees
$3.67
Current Price
$619.51M
Market Cap
52W Low$1.11
Current$3.6743.8% above low, 56.2% below high
52W High$6.94

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00---
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
No transactions in the last 3 months. Sign up free to see 12 months of history.

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Feb 27, 2026
EPS
Estimated-$0.25
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.3.29